CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.


Begin main content


Last Updated: October 18, 2005
Result type: Reports
Project Number: SR0042-000
Product Line: Reimbursement Review

Generic Name: Niacin/lovastatin

Brand Name: Advicor

Manufacturer: Oryx Pharmaceuticals Inc.

Therapeutic Area: Hypercholesterolemia and mixed dyslipidemia

Indications: Hypercholesterolemia and mixed dyslipidemia

Submission Type: Initial

Project Status: Complete

Date Recommendation Issued: April 26, 2006

Recommendation Type: List